[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyaluronic-acid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyaluronic-acid":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,41,67,101,125,151,175,199,221,252,295,319,343,368],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643880","intraarticular-injection-of-botox-and-hyaluronic-acid-in-knee-osteoarthritis-100643880",false,"NCT07666347","Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Both genders.\n* Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis.\n* Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.\n\nExclusion Criteria:\n\n* History of intra-articular injection within the last 6 months,\n* History of surgery on the knee joint or major trauma to the lower limb causing fracture.\n* Body mass index (BMI) more than 40 kg\u002Fm2.\n* Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout.\n* Diabetic patient.\n* Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection.\n* Hypersensitivity to Botulinum toxin or hyaluronic acid.","ALL","50 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.",[25,26,27,28],"Intraarticular Injection","Botox","Hyaluronic Acid","Knee Osteoarthritis","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":30,"type":33},{"date":36,"type":19},"2026-12-01",{"name":38,"class":39},"Tanta University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100442290","efficacy-at-one-year-of-combined-injections-of-plasma-rich-in-platelets-and-hyaluronic-acid-in-knee-osteoarthritis-100442290","NCT05039463","Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis","ISPAG","Inclusion Criteria:\n\n* age : \\> 18 years old\n* Patients benefiting, in the context of knee osteoarthritis, from viscosupplementation alone or from two injections of PRP, in combination with HA, at the Amiens University Hospital.\n\nExclusion Criteria:\n\n* Patient refusal to use the data\n* Language barrier\n* Age less than 18 years old.","18 Years",{"count":50,"type":19},100,"OBSERVATIONAL","The French Society of Rheumatology cannot rule on the value of intra-articular injections of PRP due to the lack of hindsight and insufficient data. In fact, the injection protocols are very heterogeneous in terms of preparation method, the presence or not of leukocytes, the number of centrifugations, the volume injected, the ultrasound guidance, which makes it difficult to analyze the literature. The investigator objective is therefore to evaluate the effectiveness of combined injections of PRP and hyaluronic acid.",[28,27,54],"Platelet Rich Plasma",[56,57,28],"platelet rich plasma","hyaluronic acid","2026-06-12",{"date":60,"type":33},"2026-06-15",{"date":62,"type":33},"2021-08-16",{"date":64,"type":19},"2026-06",{"name":66,"class":39},"Centre Hospitalier Universitaire, Amiens",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":20,"phases":77,"briefSummary":78,"conditions":79,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100637561","hyaluronic-acid-as-an-adjunct-to-non-surgical-periodontal-therapy-in-smokers-100637561","NCT07597213","Hyaluronic Acid as an Adjunct to Non-Surgical Periodontal Therapy in Smokers","The Effect of Adjunctive Use of Hyaluronic Acid in Non-Surgical Periodontal Treatment in Smoking Patients","Inclusion Criteria:\n\n1. Individuals who sign the informed consent form\n2. Participants who are systemically healthy\n3. Participants who smoke (for \\>5 years and ≥10 cigarettes per day)\n4. Participants diagnosed with Stage III or Stage IV periodontitis\n5. Participants with at least 20 natural teeth present in the mouth (excluding third molars)\n6. Participants with two non-adjacent interproximal sites in each quadrant of either jaw, presenting probing depth (PD) and clinical attachment level (CAL) ≥6 mm, and with no caries, restorations, or furcation involvement\n\nExclusion Criteria:\n\n1. Individuals who do not sign the informed consent form\n2. Individuals having any systemic disease\n3. Participants who have used antibiotics within the last 3 months\n4. Participants who have received any periodontal treatment within 6 months prior to the study\n5. Participants who are pregnant or lactating","65 Years",{"count":76,"type":19},23,[22],"The goal of this clinical trial is to evaluate whether hyaluronic acid (HA) improves periodontal healing in people with periodontal disease who smoke. Moreover, the effects of HA on biomolecules and bacteria levels will be assessed during the follow up period.\n\nThe main questions it will answer are:\n\nWill periodontal sites treated with HA gel after non-surgical periodontal treatment (NSPT) lead to better outcomes in clinical parameters compared to the sites treated with NSPT only in smokers?\n\nWill adjunctive use of HA gel reduce oxidative stress markers and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* first receive full-mouth NSPT then, randomization will be performed in selected jaw to determine the test sites. These two interproximal test sites will additionally receive HA gel application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for Metallothionein (MT) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and subgingival samples for periodontal pathogens.",[27,80,81,82,83,84,85],"Periodontal Therapy","Oral Microbiota","Oxidative Stress","Metallothionein","8-OHdG","Periodontitis",[57,87,88,89,84,90,91],"periodontitis","periodontal pathogens","metallothionein","Non-surgical periodontal treatment","split-mouth study","NOT_YET_RECRUITING","2026-06-03",{"date":95,"type":33},"2026-06-05",{"date":64,"type":19},{"date":98,"type":19},"2028-07",{"name":100,"class":39},"Marmara University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":74,"enrollmentInfo":108,"targetDuration":4,"studyType":20,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":124,"locationsCount":40},"100643782","adjunctive-hyaluronic-acid-gel-in-non-surgical-periodontal-treatment-of-patients-with-diabetes-mellitus-100643782","NCT07631273","Adjunctive Hyaluronic Acid Gel in Non-Surgical Periodontal Treatment of Patients With Diabetes Mellitus","The Effect of Hyaluronic Acid on Non-Surgical Periodontal Treatment in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Individuals who sign the informed consent form\n* Participants diagnosed with diabetes mellitus (HbA1c %7-7.9)\n* Participants without any systemic disease other than DM\n* Participants diagnosed with Stage III or Stage IV periodontitis\n* Nonsmokers\n* Participants with at least 15 natural teeth present in the mouth (excluding third molars)\n* Participants in either of the jaws, in both quadrants, having two non-adjacent interproximal sites with probing depth and clinical attachment level ≥6 mm with no caries, restorations or furcation involvement\n\nExclusion Criteria:\n\n* Individuals who do not sign the informed consent form\n* Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis\n* Participants have received any periodontal treatment within 6 months prior to the study\n* Participants who have used antibiotics within the last 3 months\n* Smokers\n* Participants who are pregnant or lactating",{"count":76,"type":19},[22],"The goal of this clinical trial is to evaluate whether the adjunctive use of hyaluronic acid (HA) improves periodontal healing in people with diabetes mellitus and periodontitis. The effects of HA on biomolecules and bacteria levels will be assessed during the follow-up period.\n\nThe main questions the study will answer are:\n\n* Will periodontal sites treated with non-surgical periodontal treatment (NSPT) plus HA gel show better clinical periodontal parameters than sites treated with only NSPT in patients with diabetes and periodontitis?\n* will HA gel have additional effect on reducing inflammation or collagen markers, and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* provide recent HbA1c test results.\n* then, the participants will receive full-mouth NSPT then, randomization will be performed for the selected jaw for test sites. These two interproximal test sites will additionally receive HA application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels and subgingival samples for periodontal pathogens.",[85,112,27,81,113,114],"Diabetes Mellitus","IL-34","β-CTX",[85,116,117,27,118,113,114,88],"diabetes mellitus","Non-surgical Periodontal Treatment","Split-mouth Study","2026-06-02",{"date":121,"type":33},"2026-06-08",{"date":64,"type":19},{"date":98,"type":19},{"name":100,"class":39},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":15,"minAge":48,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100567238","phase-2-effect-of-txa-on-reducing-bruising-after-filler-injection-100567238","NCT06665594","Effect of TXA on Reducing Bruising After Filler Injection","Does TXA Reduce Bruising After Hyaluronic Acid Filler Injection? A Prospective Half Face Study","Inclusion Criteria:\n\n* Age equal to or greater than 18 but less than or equal to 89 years.\n* Participants interested in facial filler (HA) injection.\n* English speaking.\n\nExclusion Criteria:\n\n* Minors or under the age of 18\n* Participant over the age of 89\n* Pregnant or breast-feeding women\n* Individuals unable to give consent due to another condition such as impaired decision-making capacity.\n* Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis\n* Participants undergoing unilateral facial filler (HA) injection\n* Participants with history of hypersensitivity to TXA or any of the other ingredients\n* Participants that are on current therapeutic anticoagulation therapy and aspirin use\n* Participants with stage 2 or greater renal failure\n* Participants on hemodialysis or peritoneal dialysis\n* History of diabetes or seizures\n* Current tobacco smokers\n* Acquired defective color vision",true,"89 Years",{"count":135,"type":19},40,[137],"PHASE2","The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is:\n\n* Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?\n\nParticipants will receive the study medication along with the standard facial filler injection and complete surveys.",[140,27,141],"Facial Filler Injections","Tranexamic Acid","2026-05-19",{"date":144,"type":33},"2026-05-20",{"date":146,"type":33},"2025-12-05",{"date":148,"type":19},"2026-11",{"name":150,"class":39},"University of Wisconsin, Madison",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":15,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100630389","the-efficacy-and-safety-of-a-single-dose-hyaluronic-acid-injection-in-the-treatment-of-knee-osteoarthritis-100630389","NCT07487038","The Efficacy and Safety of a Single-Dose Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis","Efficacy and Safety of a Single-Dose Hyaluronic Acid Injection in Adults With Symptomatic Knee Osteoarthritis: A Retrospective Study","ESSDHAITKO","Inclusion Criteria:\n\n* Participants who have provided written informed consent.\n* Male and female participants aged 40 to 70.\n* Bilateral or unilateral, painful, primary knee osteoarthritis.\n* Knee pain lasting at least 4 weeks while standing, walking, and\u002For moving, and the presence of at least one of the following features on an X-ray taken within the last 3 months: tibiofemoral osteophytes, femoral or tibial endplate osteosclerosis, or narrowing of the joint space (Kellgren-Lawrence grade 2-3).\n* Baseline Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score (sum of five 100-mm components) between 200 and 400 mm.\n* Individuals deemed by the investigator to be able to adhere to the visit schedule.\n* Discontinuation of all NSAIDs, corticosteroids, and other pain relievers, including over-the-counter medications, herbal treatments, or chondroprotective agents prior to injection, and no use of these during the study follow-up period (except for acetaminophen).\n* Patients who have not received another intra-articular injection in the knee or participated in a physical therapy program during the follow-up period.\n\nExclusion Criteria:\n\n* Participants hospitalized in the hospital.\n* Participants with inflammatory knee conditions other than OA (e.g., rheumatoid arthritis, chronic hemochromatosis, sickle cell anemia, and\u002For chondrocalcinosis, as well as arthropathies associated with systemic diseases such as gout and hemophilia, and infectious joint disease).\n\nThe presence of significant joint effusion identified by the investigator during a clinical examination and confirmed by an ultrasound examination performed on each patient to determine the presence of effusion\n\n* Body mass index (BMI) \\>35 kg\u002Fm²\n* Severe misalignment of the knee axis (i.e., \\>12° severe varus or valgus deformity and\u002For clinically significant moderate to severe instability).\n* Clinical findings of hip osteoarthritis (OA) and\u002For hip joint replacement on the same side as the affected knee. Hip joint replacement on the opposite side of the affected knee is not exclusionary, provided the patient does not have symptomatic hip OA.\n* Surgical intervention on the symptomatic knee within the previous 12 months (including joint replacement) or arthroscopy of the symptomatic knee within the past 3 months (note: joint replacement of the contralateral knee is permitted if performed more than 12 months prior and the participant does not report pain of ≥ 20 mm on the WOMAC pain subscale).\n* Intra-articular (IA) injections in both knees within the past 4 weeks (e.g., corticosteroids, chondroprotective agents).\n* Changes to current medications or the addition of new medications to treat knee OA within the past 4 weeks (i.e., a change in dose or regimen lasting at least 4 weeks).\n* Regular use of opioid pain relievers for pain management. Use of long-acting pain relievers such as analgesic patches, methadone, and levorphanol at any time","40 Years","70 Years",{"count":162,"type":19},133,"HA therapy typically consists of several intra-articular injections administered at weekly intervals. A single-dose IA-HA treatment offers patients and physicians a treatment option that involves both lower costs and fewer clinic visits. Furthermore, considering the administration procedure, we believe that single-dose therapy helps reduce the risk of potential side effects.\n\nIn light of this information, our study aims to retrospectively evaluate the efficacy and safety of HA in patients with symptomatic knee OA who have received a single-dose intra-articular HA injection.",[165,27],"Knee Osteoarthristis","2026-04-24",{"date":168,"type":33},"2026-04-29",{"date":170,"type":19},"2026-05-01",{"date":172,"type":19},"2026-05-15",{"name":174,"class":39},"Fatih Sultan Mehmet Training and Research Hospital",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":132,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":20,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100631112","is-cross-linked-hyaluronic-acid-a-biologic-alternative-for-alveolar-ridge-preservation-100631112","NCT07496437","Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation?","Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? A Single-blind, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n(1) Patients elder than 18 years in need of (2) maxillary non-molar tooth extraction, and (3) later rehabilitation with delayed implant installation.\n\nExclusion Criteria:\n\n(1) Patients with chronic diseases (e.g., uncontrolled diabetes mellitus, etc.) and\u002For (2) taking any medication, influencing hard or soft-tissue healing; (3) acute pain\u002Finfection or (4) presence of a fistula at the extraction site; (5) untreated periodontal disease; (6) \\>25% of the buccal bone plate missing after tooth extraction; (7) pregnancy; (8) history of hypersensitivity or allergy to xHyA or xenogenic bone substitute material; and (9) inability to attend the follow-up appointments.",{"count":183,"type":19},48,[22],"Even after atraumatic tooth removal and\u002For immediate implant placement, some reduction of the alveolar ridge dimension is expected. To counteract (or limit) this reduction, alveolar ridge preservation technique (ARP) was developed. However, standard ARP techniques, such as grafting with bone substitutes, have some concerns, such as a long healing time prior to implant installation, residual graft particles, and often the need of re-grafting at implant installation. To overcome some of these limitations biologics have been discussed as an alternative approach, such as cross-linked hyaluronic acid (xHyA). However, whether the use of biologics only can achieve comparable results to the standard techniques, has yet to be answered.\n\nThe aim of the present single-blind, randomized controlled clinical trial is to test non-inferiority in terms of mid-buccal alveolar ridge height resorption 4 months after ARP between 1) control\u002Fstandard treatment (i.e., grafting with bone substitutes and socket seal) and 2) test treatment (i.e., xHyA applied with a collagen sponge and socket seal) at maxillary non-molar teeth.\n\nForty-eight patients will be included and randomly assigned to one of the following 2 groups: 1) control group: standard ARP with deproteinized bovine bone material and covering of the socket with a free gingival graft (FGG) (n=24), 2) test group: application of xHyA soaked in a collagen sponge and covered by a FGG (n=24). The primary outcome parameter is the extent of mid-buccal alveolar ridge height resorption after 4 months, i.e., prior to implant installation, and the sample size calculation is based on a non-inferiority limit of 0.6 mm. The secondary outcome parameters are frequency of additional grafting at implant installation due to 1) a bony dehiscence or fenestration, 2) a thin buccal bone (\\\u003C 1.5 mm), or 3) contour improvement, cervical alveolar ridge width, alveolar ridge volume, histomorphometric assessment of alveolar ridge healing, feasibility of implant installation, aesthetic outcome parameters, patient reported outcome measures, changes in keratinized mucosa width, soft tissue healing, and assessment of postoperative complications. Patients will be followed up to 1 year after prosthetic restoration.",[187,188,189,27],"Alveolar Bone Resorption","Alveolar Ridge Enlargement","Tooth Extraction","2026-03-22",{"date":192,"type":33},"2026-03-27",{"date":194,"type":19},"2026-04-01",{"date":196,"type":19},"2028-12-31",{"name":198,"class":39},"Medical University of Vienna",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":15,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":20,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":40},"100589911","the-effect-of-hyaluronic-acid-injection-on-tnf-alpha-and-il-1-in-knee-osteoarthritis-100589911","NCT06960564","The Effect of Hyaluronic Acid Injection on TNF-Alpha and IL-1β in Knee Osteoarthritis","Investigation of the Effect of Hyaluronic Acid Injection on Tnf-Alpha and IL-1beta at DNA-Protein Level in Knee Osteoarthritis Patients and Comparison With Clinical Parameters: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of knee osteoarthritis according to ACR (American College of Rheumatology) criteria\n* Knee pain for more than 3 months\n* Presence of knee pain resistant to conservative treatment for at least 3 months\n* To be between the ages of 45-75\n* Kellgren-Lawrence stage 2-3 gonarthrosis detected in the available knee direct radiographs of the patients\n\nExclusion Criteria:\n\n* Patients with KL stage 1 and 4 OA\n* Systematic diseases (severe cardiovascular disease, severe renal failure, severe hepatic failure, uncontrolled diabetes, cancer, immunosuppression, haematological diseases, systemic bone diseases)\n* Bleeding tendency (acquired or inherited) \\[lNR\\>2 in a patient on Coumadin\\],\n* Infection (systemic or local)\n* Secondary knee osteoarthritis (inflammatory joint disease, post-traumatic, post-infectious, etc.)\n* Major knee trauma within the last 1 year\n* BMI \\>40\n* History of total knee or hip arthroplasty within 1 year\n* Pregnancy\n* History of intra-articular injection within the last 6 months\n* Patients with Hb less than 11 g\u002Fdl and Plt less than 150.000\n* Presence of allergy to hyaluronic acid products","45 Years","75 Years",{"count":18,"type":19},[22],"In this study, the effect of intra-articular HA injection therapy on pre- and post-treatment TNF-alpha and IL-1beta levels and methylation changes in blood and synovial fluid in patients with knee osteoarthritis will be determined and compared with the placebo group. In addition, the effects of HA injection on pain, functional status and quality of life will be evaluated and these effects will be related to changes in TNF-alpha and IL-1-beta.",[28,27],"2026-01-08",{"date":214,"type":33},"2026-01-09",{"date":216,"type":33},"2025-05-12",{"date":218,"type":19},"2026-03-29",{"name":220,"class":39},"Istanbul University",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":15,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":20,"phases":231,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100600619","hyaluronic-acid-and-polynucleotides-in-ridge-preservation-100600619","NCT07099846","Hyaluronic Acid and Polynucleotides in Ridge Preservation","The Use of Hyaluronic Acid and Polynucleotides in Ridge Preservation Sites Rehabilitated With a Complete Full Digital Workflow","P-005","Inclusion Criteria:\n\n* ≥25-year-old males and females;\n* good systemic health (self-assessment);\n* presence of an unrestorable\u002Fhopeless tooth with periodontal attachment and buccal bone preserved at least for 2\u002F3rd of the root and not associated with acute periapical pathology;\n* full mouth bleeding and plaque scores ≤ 25%\n\nExclusion Criteria:\n\n* uncontrolled or untreated periodontal disease;\n* history of local (head and neck) radiation therapy in the past 5 years;\n* acute endodontic lesion in the test tooth or in the neighbouring areas to the extraction procedure (sites with presence of an asymptomatic chronic lesion are eligible);\n* medical history that includes uncontrolled diabetes or hepatic or renal disease, or other serious medical conditions that can impact on bone metabolism (e.g. rheumatoid arthritis, osteoporosis) or transmittable diseases (e.g. HIV-related disease);\n* history of alcohol or drug abuse;\n* smokers of ≥10 cigarettes a day;\n* self-reported pregnancy or lactation.","25 Years",{"count":135,"type":19},[22],"The aim of this study is to test the use of a bovine-derived bone graft combined with a polynucleotides-rich hyaluronic acid (PNHA) gel for the preservation of the bone after a tooth extraction (alveolar ridge preservation) and to test the performance of a fully-digital workflow to rehabilitate the site with a dental implant. 40 patients in need for a single tooth extraction will be recruited at Centro di Odontoiatria, Università di Parma and they will be randomly assigned to 2 groups: extraction and spontaneous healing or extraction and regeneration of the site with a bovine-derived bone graft combined with a PNHA gel. At 4 months after extraction an implant will be placed in the extraction site, which will be rehabilitated with a fully-digital workflow and patients will be followed up at up to 12 months post rehabilitation. Two 3D x-rays with a small field of view will be performed immediately after extraction and at 4 months post extraction to plan implant placement. These images will also be used to assess changes in the dimension of the post extraction bone (primary outcome). As part of the study different questionnaires will be administered to assess quality of life and perception of the therapy and the wound exudate in the area of the extraction will be collected non invasively with a collagen sponge to assess the expression of different proteins during the early healing days. On the day of implant placement a sample of bone tissue will also be collected as part of the bone drilling and histologically analysed.",[234,235,27,236],"Socket Preservation","Implant-supported Single Crowns","CAD-CAM",[238,57,239,240,236,241],"alveolar ridge preservation","polynucleotides","digital workflow","Implant rehabilitation","2025-09-01",{"date":244,"type":33},"2025-09-08",{"date":246,"type":33},"2025-06-09",{"date":248,"type":19},"2028-05",{"name":250,"class":39},"University of Parma",2,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":259,"minAge":48,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":20,"phases":262,"briefSummary":263,"conditions":264,"keywords":278,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":40},"100593584","impact-of-nipple-reconstruction-in-mastectomized-patients-using-cross-linked-hyaluronic-acid-injection-100593584","NCT07008339","Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.","RECHIAL","* Quantitative Phase\n* Inclusion Criteria:\n\nWomen over 18 years of age, or with parental or legal guardian consent.\n\nAt least one of the following criteria:\n\nWomen undergoing their first nipple-areola complex (NAC) reconstruction through micropigmentation and\u002For:\n\nNo previous neo-nipple surgery, either unilaterally or bilaterally.\n\nSurgical reconstruction of the areola.\n\nSurgical reconstruction of the NAC with subsequent retraction of the neo-nipple.\n\nMore than 6 months since their last surgery.\n\n\\- Exclusion Criteria:\n\nAllergy to hyaluronic acid.\n\nPoor tolerance to needle injections.\n\nWithdrawal Criteria:\n\nParticipant's voluntary decision.\n\nComplications associated with the technique (allergy, hematoma, etc.).\n\nClinical deterioration preventing the woman from continuing in the study.\n\n\\- Qualitative Phase\n\nParticipant Profile Characteristics: For the qualitative phase, women who have received NAC reconstruction with HA will be invited to participate, following the maximum variation criterion. To ensure the inclusion of participants with diverse characteristics and capture a wide range of perspectives and experiences on the phenomenon under study, women of varying ages, with different breast cancer diagnoses, and histories of various oncological, surgical, and therapeutic treatments will be selected.","FEMALE",{"count":261,"type":19},138,[22],"This study evaluates the impact of hyaluronic acid (HA) injection for nipple projection following mastectomy, as a complement to areola micropigmentation. While micropigmentation is standard in nipple-areola complex (NAC) reconstruction, HA use remains novel, with limited data on psychosocial, sexual, and aesthetic outcomes.\n\nA sequential explanatory mixed-methods design will be used. In Phase 1, a randomized controlled trial will compare two groups: one receiving NAC micropigmentation alone (control) and the other receiving micropigmentation plus HA-based nipple projection (intervention). A total of 138 participants will be recruited at the Areolar Micropigmentation Unit of Germans Trias i Pujol University Hospital (Barcelona) over 36 months. Outcomes will include psychosocial and sexual well-being, satisfaction with breast and nipple appearance, and nipple projection, measured using the Spanish BREAST-Q, a custom satisfaction tool, and calipers.\n\nPhase 2 will involve a qualitative phenomenological study using semi-structured interviews with a purposive sample from the intervention group. Thematic analysis will explore body image, emotional and social well-being, and overall satisfaction, using NVivo software.\n\nThis is the first study assessing HA nipple reconstruction by advanced practice nurses using validated patient-reported outcomes. While the BREAST-Q is appropriate, it may not fully capture emotional nuances, justifying qualitative exploration. HA durability is estimated at 6-9 months, but residual volume and satisfaction over time remain underexplored. HA's aesthetic footprint may allow reduced dosages in future applications.\n\nThis minimally invasive technique may reduce the need for surgical nipple reconstruction. Conducting the procedure in a nurse-led setting is novel and may enhance patient-centered care and the role of nursing in post-mastectomy recovery.\n\nThe study complies with the Declaration of Helsinki and Spanish biomedical regulations. Ethical approval was obtained. Participants will provide informed consent, and data will be anonymized and securely stored.",[265,266,267,268,269,27,270,271,272,273,274,275,276,277],"Breast Neoplasms","Mastectomy","Mammaplasty","Nipple Disorder","Tattooing","Dermal Fillers","Reconstructive Surgical Procedures","Quality of Life","Self Concept","Body Image","Patient Satisfaction","Breast Reconstruction","Nipple Reconstruction",[279,266,276,280,277,281,27,270,282,269,274,272,283,284,275,285],"Breast Cancer","Nipple-Areola Complex Reconstruction","Areola Reconstruction","Micropigmentation","Postmastectomy Reconstruction","Cross-linked Hyaluronic Acid","Breast Cancer Survivors","2025-06-04",{"date":288,"type":33},"2025-06-06",{"date":290,"type":33},"2023-06-02",{"date":292,"type":19},"2029-07-02",{"name":294,"class":39},"Germans Trias i Pujol Hospital",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":20,"phases":304,"briefSummary":305,"conditions":306,"keywords":309,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":40},"100522083","comparison-of-04-hyaluronic-acid-solution-versus-hydroxyethylamide-solution-in-submucosal-endoscopic-resections-100522083","NCT06077981","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections of Superficial Malignant Esophageal Neoplasms: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Superficial esophageal adenocarcinoma or squamous cell carcinoma with indication of ESD after discussion in a multidisciplinary oncological board\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Residual or recurrent esophageal lesions\n* Ulcerated esophageal lesions\n* Patients with severe cardiovascular, kidney or liver disease\n* History of hypersensitivity to hyaluronic acid\n* Pregnant or lactating women",{"count":303,"type":19},30,[22],"This is a randomized, single-center clinical trial that will compare the efficacy of two substances used in the submucosal cushion formation stage of endoscopic submucosal resections of early esophageal malignant neoplasms. Such substances are hyaluronic acid in the form of TS-905 Blue Eyeₒ and hydroxyethylamide (Voluven®).",[307,308,27],"Esophageal Neoplasms","Endoscopic Mucosal Resection",[307,308,27],"2025-04-29",{"date":312,"type":33},"2025-05-01",{"date":314,"type":33},"2023-06-19",{"date":316,"type":19},"2026-04-13",{"name":318,"class":39},"Instituto do Cancer do Estado de São Paulo",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":132,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":20,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":4},"100584436","a-modern-non-surgical-method-for-treating-papillary-deficiencies-is-the-use-of-hyaluronic-acid-which-have-demonstrated-encouraging-outcome-subperiosteal-hyaluronic-acid-injection-overlay-technique-with-the-idea-of-merging-hyaluronic-acid-injection-with-surgical-intervention-to-reconstruct-idp-100584436","NCT06889311","A Modern, Non-surgical Method for Treating Papillary Deficiencies is the Use of Hyaluronic Acid, Which Have Demonstrated Encouraging Outcome. Subperiosteal Hyaluronic Acid Injection Overlay Technique with the Idea of Merging Hyaluronic Acid Injection with Surgical Intervention to Reconstruct Idp","Evaluation of Subperiosteal Hyaluronic Acid Injection Overlay Technique Compared to Tunneling with Connective Tissue Graft in Management of Interdental Papillary Defects: a Randomized Clinical Trial","Inclusion Criteria:\n\n\\- 1. Patients aged over 18 years. 2. Class I papillary recession according to the Nordland and Tarnow classification system. (Nordland and Tarnow 1998) 3. Patients free from any systemic conditions that may affect healing. (Hamadeh et al. 2024).\n\n4\\. The distance between the contact point to alveolar crest between 5 to 7 mm. 5. Presence of the adjacent teeth. 6. Compliant patients with good oral hygiene.\n\nExclusion Criteria:\n\n\\- 1. Smokers. 2. Pregnant females. 3. Patients with active periodontal disease. 4. Patients who has spacing or crowding between the teeth to be treated. 5. Abnormal tooth shape or adjacent teeth with caries. 6. Presence of proximal restoration or orthodontic appliances or fixed prosthesis.\n\n7\\. Patients with poor oral hygiene according to plaque index score of 2.0 to 3.0 evaluated according to the criteria of Silness and Loe.",{"count":327,"type":19},38,[22],"The interdental papilla is a crucial part of an esthetic smile, its loss results in gingival black triangles giving unpleasant appearance which directly affect patient self-esteem (Lee et al. 2016). The presence of interdental papilla is of great concern for the clinician and the patient. Gingival black triangles are considered to be the most disliked esthetic issue. As well open embrasures can cause food impaction and phonetic problems (Prato et al. 2004).\n\nThe treatment of black triangles is challenging in modern dentistry. The treatment options are surgical and non-surgical. Surgical treatments are invasive and do not always give a predictable result due to limited blood supply of the papilla (Mansouri 2013).\n\nHowever, no technique has been set up as a gold standard treatment for gingival black triangles, although, connective tissue graft surgical techniques are the most common used approaches for treatment of black triangles (RahimiRad 2018).\n\nA modern, non-surgical method for treating papillary deficiencies is the use of hyaluronic acid, which have demonstrated encouraging outcome (Ni et al. 2021). Subperiosteal hyaluronic acid injection overlay technique was proposed by Spano et al, (2020) with the idea of merging hyaluronic acid injection with simple surgical intervention to reconstruct the lost interdental papilla. As far as we know, there is no present studies comparing hyaluronic acid overlay technique with connective tissue graft in treatment of interdental papilla deficiencies.",[331,27],"Interdental Papillae Reconstruction",[333],"Hyaluronic acid, Interdental papilla, Black triangle","2025-03-17",{"date":336,"type":33},"2025-03-21",{"date":338,"type":19},"2025-07",{"date":340,"type":19},"2027-07",{"name":342,"class":39},"Cairo University",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":15,"minAge":350,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":20,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":40},"100545291","oral-supplementation-compared-with-hyaluronic-acid-infiltration-in-rotator-cuff-tendinopathies-100545291","NCT06379997","Oral Supplementation Compared With Hyaluronic Acid Infiltration in Rotator Cuff Tendinopathies","Efficacy of Oral Hyaluronic Acid and Collagen Supplementation Compared With Hyaluronic Acid Infiltration Treatment in Rotator Cuff Tendinopathies: A Prospective Study","Inclusion Criteria:\n\n* Persistent shoulder pain lasting for at least 2 months unresponsive to conservative treatment (nonsteroidal anti-inflammatory drugs \\[NSAIDs\\] and rehabilitation)\n* Ultrasound or MRI evidence of a rotator cuff lesion without complete tendon rupture\n* Limited active range of motion (ROM) in the shoulder\n\nExclusion Criteria:\n\n* Traumatic shoulder injury as the cause of pain\n* History of shoulder dislocation, fracture, or previous shoulder surgery\n* Presence of signs indicating ligamentous instability\n* Severe shoulder arthrosis, adhesive capsulitis, or calcific tendinitis\n* Previous infiltrative treatment with corticosteroids, hyaluronic acid, or collagen within the past 6 months\n* Diagnosis of rheumatic or neoplastic diseases\n* Ongoing therapy with anticoagulants\n* Cervical radiculopathy\n* Pregnancy\n* History of heart, kidney, or liver failure\n* Cognitive impairment","30 Years","80 Years",{"count":18,"type":19},[22],"The present study aims to investigate the effectiveness of oral supplementation with a nutraceutical containing Collagen, Hyaluronic Acid, Vitamin C, and Manganese in functional outcome and pain reduction in cases of shoulder rotator cuff tendinopathy compared to a cycle of intra-articular hyaluronic acid injections.\n\nThe project involves the recruitment of 50 adult individuals presenting with shoulder pain and instrumental evidence of rotator cuff tendinopathy. All participants will receive one intra-articular injection of 1 ml of triamcinolone acetonide 40 mg. After the injection, participants will be divided into two groups according to Good Clinical Practice guidelines. One group will begin taking one vial per day for 56 days of an oral supplement containing Hyaluronic Acid, Collagen, Vitamin C, and Manganese (HA-COL) (Tendogenial®, B2Pharma) starting from the day following enrollment (Group 1). The other group will undergo a cycle of 3 intra-articular injections with hyaluronic acid (HA) (Hyalotend®, Fidia) (Group 2).\n\nThe hypothesis is that oral supplementation with HA-COL may have the same efficacy as intra-articular hyaluronic acid treatment in reducing pain and improving shoulder functionality.\n\nFunctional assessments will be conducted by a clinician unaware of the participants' group assignment. The following assessment scales will be used:\n\nNumeric Rating Scale (NRS) for pain (from 0 to 10), evaluating 3 aspects of pain: 1) pain at rest, 2) nocturnal pain, 3) pain during movement.\n\nShoulder Disability Questionnaire (SDQ) for functionality.\n\nAssessments will be conducted at the following time points:\n\nT0) Before the administration of corticosteroid intra-articular injection (baseline).\n\nT1) Seven days after the start of HA-COL intake for Group 1 and before the first intra-articular HA injection for Group 2 (T1, seven days from T0).\n\nT2) At mid-cycle of oral HA-COL supplementation for Group 1 (28 days of intake) and seven days after the last HA injection for Group 2 (T2, 21 days from T1).\n\nT3) Follow-up at 28 days from T2, at the end of the 56-day oral treatment cycle for Group 1, and 28 days after the last injection for Group 2 (T3, 56 days from T0).",[356,27,357,358],"Tendinitis of Shoulder","Dietary Supplements","Shoulder Pain","2024-08-27",{"date":361,"type":33},"2024-08-29",{"date":363,"type":33},"2024-08-10",{"date":365,"type":19},"2025-12-31",{"name":367,"class":39},"I.R.C.C.S. Fondazione Santa Lucia",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":15,"minAge":375,"maxAge":351,"enrollmentInfo":376,"targetDuration":4,"studyType":20,"phases":378,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":40},"100555133","phase-4-cross-linked-and-non-cross-linked-hyaluronic-acid-in-subdeltoid-bursitis-100555133","NCT06508125","Cross-linked and Non-cross-linked Hyaluronic Acid in Subdeltoid Bursitis","Comparing the Efficacy of Cross-Linked and Non-Cross-Linked Hyaluronic Acid in Treating Subdeltoid Bursitis: A Double-Blind, Randomized Clinical Trial","Inclusion Criteria:\n\n* clinical diagnosis of subdeltoid bursitis\n* age 20 or older 20\n* at least one positive in the painful arc, neer test, or Hawkins test\n* can attend three months of intervention and follow-up\n\nExclusion Criteria:\n\n* history of malignancy\n* previous shoulder operation or injury\n* previous shoulder injections in the past three months","20 Years",{"count":377,"type":19},52,[379],"PHASE4","This study aims to compare the efficacy of different structures of hyaluronic acid, namely cross-linked and non-cross-linked hyaluronic acid, in treating subdeltoid bursitis.",[382,27],"Subdeltoid Bursitis",[382,384,385],"Hyaluronic acid","cross linked","2024-07-18",{"date":388,"type":33},"2024-07-19",{"date":390,"type":19},"2024-07-25",{"date":392,"type":19},"2024-12-31",{"name":394,"class":39},"Taipei Medical University"]